DataMeds AI, Inc. Cost of Revenue
DataMeds AI, Inc. (MEDS) reported Cost of Revenue of $1.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-17
- DataMeds AI, Inc. cost of revenue for the quarter ending 2026-06-30 was $1.60M, a 78.07% decline year-over-year.
- DataMeds AI, Inc. cost of revenue for the quarter ending 2026-03-31 was $1.39M, a 86.34% decline year-over-year.
- DataMeds AI, Inc. cost of revenue for the quarter ending 2025-12-31 was $9.53M, a 14.65% decline year-over-year.
- DataMeds AI, Inc. cost of revenue for the quarter ending 2025-09-30 was $2.78M, a 46.01% decline year-over-year.
- DataMeds AI, Inc. cost of revenue for fiscal 2025 was $29.76M, a 81.92% increase from fiscal 2024.
- DataMeds AI, Inc. cost of revenue for fiscal 2024 was $16.36M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-17 | $2.99M 10-Q · filed 2026-08-17 | $12.51M derived: sum of 3 quarters · filed 2026-08-17 | $15.30M derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $1.39M 10-Q · filed 2026-05-19 | $10.92M derived: sum of 2 quarters · filed 2026-05-19 | $13.70M derived: sum of 3 quarters · filed 2026-05-19 | $20.98M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | $9.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $12.31M derived: sum of 2 quarters · filed 2026-03-20 | $19.59M derived: sum of 3 quarters · filed 2026-08-17 | $29.76M 10-K · filed 2026-03-20 |
| 2025-09-30 | $2.78M 10-Q · filed 2025-11-19 | $10.07M derived: sum of 2 quarters · filed 2026-08-17 | $20.24M 10-Q · filed 2025-11-19 | $31.40M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-06-30 | $7.29M 10-Q · filed 2026-08-17 | $17.46M 10-Q · filed 2026-08-17 | $28.62M derived: sum of 3 quarters · filed 2026-08-17 | $33.77M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | $10.17M 10-Q · filed 2026-05-19 | $21.33M derived: sum of 2 quarters · filed 2026-05-19 | $26.49M derived: sum of 3 quarters · filed 2026-05-19 | $26.53M derived: sum of 4 quarters · filed 2026-05-19 |
| 2024-12-31 | $11.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $16.31M derived: sum of 2 quarters · filed 2026-03-20 | $16.36M derived: sum of 3 quarters · filed 2026-03-20 | $16.36M 10-K · filed 2026-03-20 |
| 2024-09-30 | $5.15M 10-Q · filed 2025-11-19 | $5.20M derived: sum of 2 quarters · filed 2025-11-19 | $5.20M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $47.15K 10-Q · filed 2025-08-19 | $47.15K 10-Q · filed 2025-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HWH International Inc. (HWH) | United States | $0.021B | -4.08 |
| Cosmos Health Inc. (COSM) | Greece | $0.038B | -0.60 |
| NU SKIN ENTERPRISES, INC. (NUS) | United States | $0.225B | -1.18 |
| HERBALIFE LTD. (HLF) | $1.281B | 8.39 | |
| CARDINAL HEALTH INC (CAH) | United States | $51.753B | 29.38 |
| Cencora, Inc. (COR) | United States | $59.130B | 20.57 |
| MCKESSON CORP (MCK) | United States | $101.317B | 19.78 |